by Mrudula Kulkarni
2 minutes
GlaxoSmithKline Appoints Tony Wood as Chief Scientific Officer to Spearhead R&D Innovations
GlaxoSmithKline plc, has announced the appointment of Tony Wood as Chief Scientific Officer.
London, UK – August 2024 – GlaxoSmithKline plc (GSK), a leading global pharmaceutical company, has announced the appointment of Tony Wood as Chief Scientific Officer (CSO), effective August 2024. Wood will take full accountability for research and development (R&D) across GSK's extensive portfolio, playing a pivotal role in continuing the company's tradition of innovation in medicine development.
Tony Wood, who has been with GSK since 2017 after transitioning from Pfizer, brings over 30 years of experience in various R&D disciplines. At Pfizer, he was instrumental in creating and leading global organizations that supported drug discovery and development. His extensive background will be vital in driving GSK’s R&D productivity and focusing on the development of innovative therapeutic solutions.
"Tony’s deep understanding of the pharmaceutical landscape and his proven track record in leading large-scale R&D initiatives make him exceptionally well-suited to lead GSK's science efforts," said Emma Walmsley, CEO of GSK. "Under his leadership, we look forward to continuing our legacy of delivering innovative medicines that make a real difference to patients' lives."
In his new role, Wood will oversee all aspects of GSK’s research and development, ensuring that the company remains at the forefront of scientific innovation in areas such as immunology, oncology, and infectious diseases. His appointment is expected to further enhance GSK's ability to meet the health needs of the global community through groundbreaking medical breakthroughs.
For more information on GSK’s research initiatives and executive team updates, please visit GSK’s official website.
